Följ
Aikaterini Chatzidionysiou
Aikaterini Chatzidionysiou
Verifierad e-postadress på ki.se
Titel
Citeras av
Citeras av
År
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update
JS Smolen, R Landewé, J Bijlsma, G Burmester, K Chatzidionysiou, ...
Annals of the rheumatic diseases 76 (6), 960-977, 2017
57002017
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
JS Smolen, RBM Landewé, JWJ Bijlsma, GR Burmester, M Dougados, ...
Annals of the rheumatic diseases 79 (6), 685-699, 2020
25512020
Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: a meta-analysis
P Domingo, I Mur, GM Mateo, M del Mar Gutierrez, V Pomar, N de Benito, ...
Jama 326 (6), 499-518, 2021
4622021
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update
JS Smolen, RBM Landewé, SA Bergstra, A Kerschbaumer, A Sepriano, ...
Annals of the rheumatic diseases 82 (1), 3-18, 2023
4542023
Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results …
RF Van Vollenhoven, S Ernestam, P Geborek, IF Petersson, L Cöster, ...
The Lancet 374 (9688), 459-466, 2009
4252009
Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis
S Ramiro, A Sepriano, K Chatzidionysiou, JL Nam, JS Smolen, ...
Annals of the rheumatic diseases 76 (6), 1101-1136, 2017
3582017
Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has …
K Chatzidionysiou, E Lie, E Nasonov, G Lukina, ML Hetland, U Tarp, ...
Annals of the rheumatic diseases 70 (9), 1575-1580, 2011
3092011
Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel …
RF van Vollenhoven, P Geborek, K Forslind, K Albertsson, S Ernestam, ...
The Lancet 379 (9827), 1712-1720, 2012
2812012
Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of …
JL Nam, K Takase-Minegishi, S Ramiro, K Chatzidionysiou, JS Smolen, ...
Annals of the rheumatic diseases 76 (6), 1113-1136, 2017
2652017
Patient global assessment in measuring disease activity in rheumatoid arthritis: a review of the literature
E Nikiphorou, H Radner, K Chatzidionysiou, C Desthieux, C Zabalan, ...
Arthritis research & therapy 18, 1-11, 2016
2412016
Delays in assessment of patients with rheumatoid arthritis: variations across Europe
K Raza, R Stack, K Kumar, A Filer, J Detert, H Bastian, GR Burmester, ...
Annals of the rheumatic diseases 70 (10), 1822-1825, 2011
1902011
Efficacy of glucocorticoids, conventional and targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR …
K Chatzidionysiou, S Emamikia, J Nam, S Ramiro, J Smolen, ...
Annals of the rheumatic diseases 76 (6), 1102-1107, 2017
1432017
Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year …
K Chatzidionysiou, E Lie, E Nasonov, G Lukina, ML Hetland, U Tarp, ...
Annals of the rheumatic diseases 71 (3), 374-377, 2012
1192012
Effectiveness of tocilizumab with and without synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a European collaborative study
C Gabay, M Riek, ML Hetland, EM Hauge, K Pavelka, M Tomšič, ...
Annals of the rheumatic diseases 75 (7), 1336-1342, 2016
952016
Effectiveness of TNF inhibitor switch in RA: results from the national Swedish register
K Chatzidionysiou, J Askling, J Eriksson, LE Kristensen, ...
Annals of the rheumatic diseases 74 (5), 890-896, 2015
912015
Impact of the COVID-19 pandemic on morbidity and mortality in patients with inflammatory joint diseases and in the general population: a nationwide Swedish cohort study
H Bower, T Frisell, D Di Giuseppe, B Delcoigne, GM Ahlenius, ...
Annals of the rheumatic diseases 80 (8), 1086-1093, 2021
892021
Disease activity patterns over time in patients with SLE: analysis of the Hopkins Lupus Cohort
N Györi, I Giannakou, K Chatzidionysiou, L Magder, RF Van Vollenhoven, ...
Lupus science & medicine 4 (1), e000192, 2017
702017
Rituximab versus anti-TNF in patients who previously failed one TNF inhibitor in an observational cohort
K Chatzidionysiou, RF Vollenhoven
Scandinavian Journal of Rheumatology 42 (3), 190-195, 2013
662013
The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registries
DS Courvoisier, K Chatzidionysiou, D Mongin, K Lauper, X Mariette, ...
Rheumatology 60 (2), 820-828, 2021
652021
2017 EULAR recommendations for a core data set to support observational research and clinical care in rheumatoid arthritis
H Radner, K Chatzidionysiou, E Nikiphorou, L Gossec, KL Hyrich, ...
Annals of the rheumatic diseases 77 (4), 476-479, 2018
632018
Systemet kan inte utföra åtgärden just nu. Försök igen senare.
Artiklar 1–20